MARKET

OTLKW

Outlook Therapeutics Inc
OTLKW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.2941
0.0670
1.149
-
FDA Sets December 31 PDUFA Date for Outlook Therapeutics’ ONS-5010 BLA Review
Reuters · 11/13 21:17
OUTLOOK THERAPEUTICS INC: ONS-5010, IF APPROVED, WILL BE BRANDED AS LYTENAVA FOR TREATMENT OF WET AMD
Reuters · 11/13 13:30
OUTLOOK THERAPEUTICS RE-SUBMITS BIOLOGICS LICENSE APPLICATION FOR ONS-5010
Reuters · 11/03 13:35
OUTLOOK THERAPEUTICS INC - IF APPROVED, ONS-5010 TO BE BRANDED AS LYTENAVA FOR WET AMD
Reuters · 11/03 13:35
OUTLOOK THERAPEUTICS INC - TO RESUBMIT BLA BY END OF 2025
Reuters · 09/29 12:45
U.S. RESEARCH ROUNDUP-Apple, GE Aerospace, Tesla
Reuters · 09/22 07:58
OUTLOOK THERAPEUTICS INC <OTLK.O>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $8 FROM $21
Reuters · 09/22 02:45
Outlook Therapeutics Announces Departure of Chief Commercial Officer Jeff Evanson
Reuters · 09/05 21:01
More

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLKW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLKW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLKW stock methods without spending real money on the virtual paper trading platform.